An Impactful Experience With a Patient With Metastatic Breast Cancer

Kevin M. Kalinsky, MD


January 06, 2023

Kevin M. Kalinsky, MD, reflects on a meaningful experience with a patient with metastatic breast cancer that is HER2-low.

Dr Kalinsky details how the recently approved antibody-drug conjugate trastuzumab deruxtecan produced a positive response, which gave him a tremendous sense of gratification.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.